| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MCM7; CDC47; MCM2; DNA replication licensing factor MCM7; CDC47 homolog; P1.1-MCM3 |
| Entrez GeneID | 4176 |
| WB Predicted band size | Calculated MW: 81 kDa; Observed MW: 81 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human MCM7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MCM7抗体的3篇代表性文献示例(注：以下信息为模拟示例，实际文献请通过学术数据库核实)：
---
1. **文献名称**: *MCM7 expression as a marker of proliferation in colorectal cancer*
**作者**: Stoehlmacher J, et al.
**摘要**: 该研究通过免疫组化(IHC)分析MCM7抗体在结直肠癌组织中的表达，发现MCM7高表达与肿瘤细胞增殖活性及患者预后不良显著相关，提示其作为临床生物标志物的潜力。
2. **文献名称**: *Comparative analysis of MCM7 and Ki-67 antibodies in detecting proliferating cells*
**作者**: Simon NE, et al.
**摘要**: 研究比较了MCM7抗体与传统增殖标记物Ki-67在乳腺癌组织中的敏感性，结果显示MCM7在识别早期G1期细胞方面更具优势，可能成为更精准的增殖检测工具。
3. **文献名称**: *MCM7 antibody-based diagnosis in gliomas*
**作者**: Todorov IT, et al.
**摘要**: 利用MCM7抗体的Western blot和免疫荧光技术，验证了MCM7在神经胶质瘤中的过表达，并发现其表达水平与肿瘤分级正相关，为胶质瘤诊断提供新方法。
---
如需具体文献，建议通过PubMed或Google Scholar搜索关键词“MCM7 antibody”、“MCM7 biomarker”等获取最新研究。
The MCM7 (Minichromosome Maintenance Complex Component 7) antibody is a widely used tool in molecular biology and cancer research to detect the MCM7 protein, a critical component of the DNA replication machinery. MCM7 is part of the hexameric MCM2-7 complex, which acts as a licensing factor to ensure DNA replication occurs only once per cell cycle. It plays a vital role in initiating and elongating replication forks during the S phase. Dysregulation of MCM7 expression is strongly linked to uncontrolled cell proliferation, making it a biomarker of interest in cancer studies.
MCM7 antibodies are frequently employed to assess cell proliferation status, as MCM7 is overexpressed in actively dividing cells, including malignant tissues. Compared to traditional proliferation markers like Ki-67. MCM7 exhibits higher stability throughout the cell cycle, enabling more reliable detection in clinical samples. These antibodies are utilized in techniques such as immunohistochemistry (IHC), Western blotting, and immunofluorescence to study tumor progression, prognosis, and therapeutic responses in cancers like cervical carcinoma, gliomas, and prostate cancer.
Commercially available MCM7 antibodies (e.g., clone DCS-141.1) are validated for specificity against conserved epitopes across human and other mammalian species. However, variability in antibody performance across tissue types and fixation methods remains a challenge. Current research focuses on standardizing MCM7 detection protocols and exploring its potential as a diagnostic or therapeutic target in precision oncology.
×
